J&J’s Darzalex reduces disease progression in multiple myeloma study

This article was originally published here

The phase 3 MAIA study showed that the daratumumab, in combination with lenalidomide and dexamethasone (Rd), has reduced the risk of disease progression or death in patients with

The post J&J’s Darzalex reduces disease progression in multiple myeloma study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply